logo
Tokio Marine HCC and Susan G. Komen® Team Up Once Again with Golf Champion Nelly Korda to Help End Breast Cancer

Tokio Marine HCC and Susan G. Komen® Team Up Once Again with Golf Champion Nelly Korda to Help End Breast Cancer

Business Upturn25-05-2025

WAKEFIELD, Mass., May 25, 2025 (GLOBE NEWSWIRE) — With the 80th edition of the biggest women's U.S. golf tournament starting on May 29, Susan G. Komen®, the world's leading breast cancer organization, is once again proud to partner with Tokio Marine HCC (TMHCC), one of the world's leading specialty insurers, and Nelly Korda, the number one-ranked women's golfer in the world, to support efforts to end breast cancer and bring vital resources to those affected by the disease.
This year alone, it is estimated that 316,9501 women in the U.S. will be diagnosed with invasive breast cancer for the first time. Tragically, it is also expected that 42,1701 will succumb to the disease, which disregards age, gender, socio-economic status or location.
Latest research indicates that by making modern treatments accessible to everyone, roughly one-third of U.S. breast cancer deaths could be prevented. In support of this cause, TMHCC will once again support Susan G. Komen's Swing for a Cure campaign by donating $5,000 for every birdie and $10,000 for every eagle that Korda scores during the tournament, with a guaranteed minimum donation of $50,000.
Extending its support for this year's campaign, TMHCC will also donate $25,000 should Korda shoot a hole in one during the tournament, $100,000 should she win by three strokes, $500,000 should she win by four, and $1 million should she win by five or more.
'We are so excited to be spearheading this fantastic partnership again this year, extending our support for such a worthy cause. At TMHCC, a sense of responsibility and duty to our community has always been a key driving force behind our work. It is with great pride that we are able to collaborate with Susan G. Komen and Nelly Korda to raise awareness of breast cancer, fund research for critical treatment, and one day eradicate it as a life-threatening disease,' said Tokio Marine HCC's CEO Susan Rivera.
'At Susan G. Komen, we believe in the power of women supporting women — lifting each other up through challenges and triumphs alike,' said Paula Schneider, President & CEO of Susan G. Komen. 'That's why we're once again so proud to stand beside Nelly, a true champion on and off the course, helping to shine a light on the critical needs of families facing breast cancer. In fact, last year alone, thanks to the generosity of supporters like TMHCC, Komen was able to deliver nearly 43,000 direct patient services and $7.5 million in financial assistance to thousands of individuals navigating breast cancer. We're deeply grateful to TMHCC for their ongoing partnership, and we'll be cheering Nelly on every step of the way!'
To learn more, follow the campaign and make donations, please visit www.swingforcure.com.
As part of the Tokio Marine Group family, TMHCC is driven by the philosophy of 'Inspiring Confidence. Accelerating Progress.' As a socially responsible organization that looks beyond profit, TMHCC helps build more resilient economies, industries and societies in a rapidly changing world. This has been TMHCC's mission since its founding and will remain its guiding purpose.
About Tokio Marine HCC
Tokio Marine HCC is a member of the Tokio Marine Group, a premier global company founded in 1879 with a market capitalization of $74 billion as of March 31, 2025. Headquartered in Houston, Texas, Tokio Marine HCC is a leading specialty insurance group with offices in the United States, Mexico, the United Kingdom and Continental Europe. Tokio Marine HCC's major domestic insurance companies have financial strength ratings of 'A+' (Strong) from S&P Global Ratings, 'A++' (Superior) from AM Best, and 'AA-' (Very Strong) from Fitch Ratings; its major international insurance companies have financial strength ratings of 'A+' (Strong) from S&P Global Ratings. Tokio Marine HCC is the marketing name used to describe the affiliated companies under the common ownership of HCC Insurance Holdings, Inc., a Delaware-incorporated insurance holding company. For more information about Tokio Marine HCC, please visit www.tokiomarinehcc.com. Media Contact: Sean Curtin President & CUO – Contingency & SHEL Tokio Marine HCC – Specialty Group [email protected] 781.258.9232
About Susan G. Komen®
Susan G. Komen® is the world's leading nonprofit breast cancer organization, working to save lives and end breast cancer forever. Komen has an unmatched, comprehensive 360-degree approach to fighting this disease across all fronts and supporting millions of people in the U.S. and in countries worldwide. We advocate for patients, drive research breakthroughs, improve access to high-quality care, offer direct patient support and empower people with trustworthy information. Founded by Nancy G. Brinker, who promised her sister, Susan G. Komen, that she would end the disease that claimed Suzy's life, Komen remains committed to supporting those affected by breast cancer today, while tirelessly searching for tomorrow's cures. Visit komen.org or call 1-877 GO KOMEN. Connect with us on social at www.komen.org/contact-us/follow-us/.
_______________
1 https://www.komen.org/breast-cancer/facts-statistics/breast-cancer-statistics/
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

MiNK Therapeutics Announces Virtual Annual Shareholders Meeting
MiNK Therapeutics Announces Virtual Annual Shareholders Meeting

Yahoo

timean hour ago

  • Yahoo

MiNK Therapeutics Announces Virtual Annual Shareholders Meeting

NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies, today announced that its Annual Shareholders Meeting will begin at 9:30 a.m. ET. on June 18, 2025, and will be conducted in a virtual format only. Registration for attendees will start at 9:15 a.m. ET. To participate in the Annual Shareholders Meeting, shareholders should visit and enter the 16-digit control number found in their proxy materials. Guests may also access the meeting in listen-only mode. No control number is required for guests. Webcast Information: Date: Wednesday, June 18, 2025 Time: 9:30 a.m. ET A live webcast and replay will be accessible from the Company's website at and at About MiNK Therapeutics MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the development of allogeneic invariant natural killer T (iNKT) cell therapies and precision-targeted immune technologies. MiNK's proprietary platform is designed to restore immune balance and drive cytotoxic immune responses across cancer, immune-mediated diseases, and pulmonary immune failure. MiNK's lead asset, AGENT-797, is an off-the-shelf, allogeneic iNKT cell therapy currently in clinical development for the treatment of graft-versus-host disease (GvHD), solid tumors, and critical pulmonary immune collapse. MiNK is also advancing a pipeline of T cell receptor (TCR)-based therapies and neoantigen discovery tools that enable tumor- and tissue-specific immune activation with broad potential application. With a scalable, cryopreserved manufacturing process and a differentiated mechanism that bridges innate and adaptive immunity, MiNK is committed to developing next-generation immune reconstitution therapies that are accessible, durable, and applicable across a wide range of indications. For more information, visit or @MiNK_iNKT. Information that may be important to investors will be routinely posted on our website and social media channels. Investor Contact917-362-1370 investor@ Media Contact781-674-4428communications@ in to access your portfolio

Diabetic Nephropathy Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 12+ Companies and 15+ Therapies
Diabetic Nephropathy Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 12+ Companies and 15+ Therapies

Yahoo

timean hour ago

  • Yahoo

Diabetic Nephropathy Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 12+ Companies and 15+ Therapies

The diabetic nephropathy market is driven by the growing burden of diabetes and the increasing demand for effective treatments for kidney disease. Advances in therapeutics, including new drug classes with proven renal benefits, are enhancing patient outcomes and driving market growth. Rising investment in research and heightened awareness of early diagnosis and management are further contributing factors. Additionally, emerging economies with limited treatment access and aging populations offer significant growth potential. New York, USA, June 10, 2025 (GLOBE NEWSWIRE) -- Diabetic Nephropathy Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 12+ Companies and 15+ Therapies | DelveInsight The diabetic nephropathy market is driven by the growing burden of diabetes and the increasing demand for effective treatments for kidney disease. Advances in therapeutics, including new drug classes with proven renal benefits, are enhancing patient outcomes and driving market growth. Rising investment in research and heightened awareness of early diagnosis and management are further contributing factors. Additionally, emerging economies with limited treatment access and aging populations offer significant growth potential. DelveInsight's 'Diabetic Nephropathy Pipeline Insight 2025' report provides comprehensive global coverage of pipeline diabetic nephropathy therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the diabetic nephropathy pipeline domain. Key Takeaways from the Diabetic Nephropathy Pipeline Report DelveInsight's diabetic nephropathy pipeline report depicts a robust space with 12+ active players working to develop 15+ pipeline diabetic nephropathy drugs. Key diabetic nephropathy companies such as Serodus AS, Curacle, ZyVersa Therapeutics, Inc., Biocity Biopharmaceutics, Walden Biosciences, Shanghai Alebund Pharmaceuticals, Youngene Therapeutics, Certa Therapeutics, and others are evaluating new diabetic nephropathy drugs to improve the treatment landscape. Promising pipeline diabetic nephropathy therapies such as SER150, CU01, 2HPβCD, SC0062, WAL0921, AP 303, YG1805, CTA 382, and others are in different Phases of diabetic nephropathy clinical trials. In April 2025, Palatin Technologies announced that data from the Phase IIb BREAKOUT study was presented at the National Kidney Foundation Spring Meeting in Boston, MA. The poster presentation titled Efficacy of Bremelanotide (BMT) to Stabilize Podocyte Function and Reduce Proteinuria in Adults with Diabetic Type II Nephropathy. In February 2025, BioCity Biopharma announced that its ETA-Selective receptor antagonist, SC0062, met the 12-week primary endpoint of a reduction in proteinuria in the diabetic kidney disease cohort of its randomized, double-blind, placebo-controlled Phase II trial. In September 2024, Walden Biosciences announced that it had completed initial dosing of all subjects in the first cohort of a Phase II basket study evaluating WAL0921 as a treatment for chronic kidney diseases. In March 2024, ZyVersa Therapeutics announced Institutional Review Board (IRB) approval of the Phase IIa clinical trial protocol to evaluate the efficacy and safety of Cholesterol Efflux Mediator VAR 200 in patients with diabetic kidney disease. Request a sample and discover the recent advances in diabetic nephropathy drugs @ Diabetic Nephropathy Pipeline Report The diabetic nephropathy pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage diabetic nephropathy drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the diabetic nephropathy clinical trial landscape. Diabetic Nephropathy Overview Diabetic nephropathy is a serious long-term complication of diabetes that arises when elevated blood sugar levels damage the kidneys' filtering system. The kidneys are essential for removing waste from the blood, and damage to their filtering units can lead to kidney failure. This condition is a primary contributor to end-stage renal disease (ESRD), which often requires dialysis or a kidney transplant for survival. Diabetic nephropathy usually progresses slowly over several years and may remain asymptomatic until significant kidney damage has already occurred. Common symptoms of diabetic nephropathy include persistent protein in the urine (proteinuria), swelling in the hands, feet, or ankles due to fluid buildup, frequent nighttime urination (nocturia), fatigue, nausea, vomiting, loss of appetite, unexplained weight loss, and high blood pressure. As kidney function deteriorates further, patients may progress to ESRD. The main cause of this condition is prolonged high blood sugar, which damages the tiny blood vessels in the kidneys. Other contributing factors include genetic predisposition, high blood pressure, smoking, and abnormal blood lipid levels. Diagnosis involves both urine and blood tests. The urine albumin-to-creatinine ratio (UACR) helps detect early signs of protein leakage, while blood tests measuring serum creatinine and estimated glomerular filtration rate (eGFR) evaluate kidney function. Imaging techniques like ultrasound may also be used to examine the structure of the kidneys and detect any abnormalities. Risk factors for developing diabetic nephropathy include poor blood sugar control, long-term diabetes, high blood pressure, obesity, smoking, and a family history of kidney disease. Certain ethnicities, such as African Americans, Hispanics, and Native Americans, are also at higher risk. Treatment focuses on slowing kidney damage, managing symptoms, and preventing complications. This involves maintaining optimal blood sugar levels through diet, physical activity, and medications like insulin or oral antidiabetics. Controlling blood pressure is equally important and often includes the use of ACE inhibitors or ARBs, which offer kidney protection. Lifestyle changes such as quitting smoking and maintaining a healthy body weight are crucial. In later stages of the disease, dialysis or a kidney transplant may be necessary. Early detection and effective management of diabetes are key to reducing the impact of diabetic nephropathy and preserving kidney out more about diabetic nephropathy drugs @ Diabetic Nephropathy Treatment A snapshot of the Pipeline Diabetic Nephropathy Drugs mentioned in the report: Drugs Company Phase MoA RoA SER150 Serodus AS II/III Thromboxane receptor antagonists; Thromboxane synthase inhibitors Oral CU01 Curacle II TGF-β/SMAD signaling inhibitor Oral 2HPβCD ZyVersa Therapeutics, Inc. II Undisclosed Intravenous SC0062 Biocity Biopharmaceutics II ETA-Selective receptor antagonist Oral AP 303 Shanghai Alebund Pharmaceuticals I Undisclosed Oral CTA 382 Certa Therapeutics Preclinical GPR68 protein antagonists Undisclosed Learn more about the emerging diabetic nephropathy therapies @ Diabetic Nephropathy Clinical Trials Diabetic Nephropathy Therapeutics Assessment The diabetic nephropathy pipeline report proffers an integral view of the emerging diabetic nephropathy therapies segmented by stage, product type, molecule type, route of administration, and mechanism of action. Scope of the Diabetic Nephropathy Pipeline Report Coverage: Global Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Therapeutics Assessment By Route of Administration: Oral, Intravenous, Subcutaneous, Parenteral, Topical Therapeutics Assessment By Molecule Type: Recombinant fusion proteins, Small molecule, Monoclonal antibody, Peptide, Polymer, Gene therapy Therapeutics Assessment By Mechanism of Action: Thromboxane receptor antagonists, Thromboxane synthase inhibitors, TGF-β/SMAD signaling inhibitor, ETA-Selective receptor antagonist, GPR68 protein antagonists Key Diabetic Nephropathy Companies: Serodus AS, Curacle, ZyVersa Therapeutics, Inc., Biocity Biopharmaceutics, Walden Biosciences, Shanghai Alebund Pharmaceuticals, Youngene Therapeutics, Certa Therapeutics, and others. Key Diabetic Nephropathy Pipeline Therapies: SER150, CU01, 2HPβCD, SC0062, WAL0921, AP 303, YG1805, CTA 382, and others. Dive deep into rich insights for new diabetic nephropathy treatments, visit @ Diabetic Nephropathy Drugs Table of Contents 1. Diabetic Nephropathy Pipeline Report Introduction 2. Diabetic Nephropathy Pipeline Report Executive Summary 3. Diabetic Nephropathy Pipeline: Overview 4. Analytical Perspective In-depth Commercial Assessment 5. Diabetic Nephropathy Clinical Trial Therapeutics 6. Diabetic Nephropathy Pipeline: Late-Stage Products (Pre-registration) 7. Diabetic Nephropathy Pipeline: Late-Stage Products (Phase III) 8. Diabetic Nephropathy Pipeline: Mid-Stage Products (Phase II) 9. Diabetic Nephropathy Pipeline: Early-Stage Products (Phase I) 10. Diabetic Nephropathy Pipeline Therapeutics Assessment 11. Inactive Products in the Diabetic Nephropathy Pipeline 12. Company-University Collaborations (Licensing/Partnering) Analysis 13. Key Companies 14. Key Products in the Diabetic Nephropathy Pipeline 15. Unmet Needs 16. Market Drivers and Barriers 17. Future Perspectives and Conclusion 18. Analyst Views 19. Appendix For further information on the diabetic nephropathy pipeline therapeutics, reach out @ Diabetic Nephropathy Therapeutics Related Reports Diabetic Nephropathy Epidemiology Forecast Diabetic Nephropathy Epidemiology Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted diabetic nephropathy epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. Diabetic Nephropathy Market Diabetic Nephropathy Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key diabetic nephropathy companies, including Bayer, Janssen Pharmaceutical, AstraZeneca, Daiichi Sankyo, Kyowa Kirin, Teijin America, Boehringer Ingelheim, Eli Lilly and Company, Chinook Therapeutics, Abbvie, Mitsubishi Tanabe Pharma, AstraZeneca, Boehringer Ingelheim, CSL Behring, Gilead Sciences, Goldfinch Bio, Novartis Pharmaceuticals, Prokidney, among others. Diabetic Peripheral Neuropathy Market Diabetic Peripheral Neuropathy Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key diabetic peripheral neuropathy companies, including Helixmith, Aptinyx, WinSanTor, Inc., Regenacy Pharmacuticals, Novaremed Ltd., Grünenthal GmbH, Glenmark Pharmaceuticals, among others. Diabetic Peripheral Neuropathy Pipeline Diabetic Peripheral Neuropathy Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key diabetic peripheral neuropathy companies, including Apurano Pharmaceuticals, Novaremed, Trevena, Helixmith, Applied Therapeutics, WinSanTor, Centrexion Therapeutics, Praetego, among others. Type 1 Diabetes Market Type 1 Diabetes Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key type 1 diabetes companies including Landos Biopharma, Diamyd Medical, Gan&Lee Pharmaceuticals, Zealand Pharma, Kamada, AstraZeneca, Novo Nordisk, Provention Bio Preregistration, Histogen, Vertex Pharmaceuticals, Panbela Therapeutics, Arecor, Bioprojet, Novartis, ImCyse, Adocia, Anelixis Therapeutics, Tolerion, TikoMed, Avotres, REMD Biotherapeutics, Novo Nordisk, among others. DelveInsight's Pharma Competitive Intelligence Service: Through its CI solutions, DelveInsight provides its clients with real-time and actionable intelligence on their competitors and markets of interest to keep them stay ahead of the competition by providing insights into the latest therapeutic area-specific/indication-specific market trends, in emerging drugs, and competitive strategies. These services are tailored to the specific needs of each client and are delivered through a combination of reports, dashboards, and interactive presentations, enabling clients to make informed decisions, mitigate risks, and identify opportunities for growth and expansion. Other Business Consulting Services Healthcare Conference Coverage Pipeline Assessment Healthcare Licensing Services Discover how a mid-pharma client gained a level of confidence in their soon-to-be partner for manufacturing their therapeutics by downloading our Due Diligence Case Study About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. Connect with us at LinkedIn CONTACT: Contact Us Shruti Thakur info@ +14699457679

The 2025 MISTRs Are Here — and They're Hotter Than Free Online PrEP
The 2025 MISTRs Are Here — and They're Hotter Than Free Online PrEP

Yahoo

time2 hours ago

  • Yahoo

The 2025 MISTRs Are Here — and They're Hotter Than Free Online PrEP

From viral creators to queer heartthrobs, this year's MISTRs are serving face, body, and free sexual healthcare for all The 2020 MISTRs MISTR: Free online PrEP, DoxyPEP & STI Testing Miami, FL, June 10, 2025 (GLOBE NEWSWIRE) -- Things just got hotter. MISTR, the nation's #1 LGBTQ+ telehealth platform for sexual health, is proud to unveil the new class of MISTRs for 2025 — twelve bold, beautiful, and totally unfiltered ambassadors who are bringing free sexual healthcare to your feed and your bedroom. Serving more than 500,000 patients served nationwide, MISTR makes it easy to stay protected. Patients can sign up online for PrEP — a once-a-day pill that reduces the risk of HIV by 99% — and DoxyPEP, an antibiotic taken after sex that helps prevent common STIs like syphilis, chlamydia, and gonorrhea. When bundled together, they offer next-level protection — and MISTR makes it 100% free, fast, and delivered discreetly to your door. 'Being a MISTR means showing up — shirtless, fearless, and fully protected,' said Tristan Schukraft, Founder and CEO of MISTR. 'These guys are fun, fearless, and fully committed to making HIV prevention sexy and stigma-free.' This year's lineup includes digital disruptors, fitness kings, and unapologetically queer content creators — including model and LGBTQ+ heartthrob Bruno Alcantara and the sizzling creator and advocate Kyle Krieger — all teaming up with MISTR to spread the word (and maybe more). Each MISTR will appear in exclusive video content, social collabs, and events promoting MISTR's 100% free online access to PrEP, DoxyPEP, STI testing, and long-term HIV care – all available online at with or without insurance. The full 2025 MISTR roster: Bruno Alcantara Harold Cabrera Ruiz Chase Carlson Christian Dante White Dany Juvier Kyle Krieger Jordan Lipes David Oberto Robert Pérez Ty Talley Doryin Thames Dru Vu Together, they'll be showing the world that taking care of your sexual health doesn't have to be boring, awkward, or expensive. It can be hot, fast, free, and delivered to your door. Follow the campaign at @heymistr, and visit to get on PrEP or DoxyPEP with zero cost, zero judgment, and zero excuses. # # # ABOUT MISTRMISTR is a telemedicine platform offering free online access to pre-exposure prophylaxis (PrEP) DoxyPEP, STI Testing and long-term HIV care in all 50 states, D.C. and Puerto Rico. Gay owned and operated, MISTR has brought together a network of the best doctors, pharmacists, and problem solvers to make PrEP, DoxyPEP and long-term HIV care available to all who need it. No doctor's office, no paperwork and free delivery. Learn more at Attachments The 2020 MISTRs MISTR: Free online PrEP, DoxyPEP & STI Testing CONTACT: Brian Rosman MISTR 323.443.7780 mistr@

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store